Here's a question.
If Efti is approved in 2027 in this combo with keytruda and chemo for NSCLC trial, does that increase Keytruda's patent across the board or just for use with efti and chemo in NSCLC?
- Forums
- ASX - By Stock
- IMM
- Ann: Immutep announces Ph 3 clinical trial collaboration with MSD
Ann: Immutep announces Ph 3 clinical trial collaboration with MSD, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $581.0M |
Open | High | Low | Value | Volume |
41.0¢ | 41.5¢ | 39.5¢ | $1.576M | 3.906M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2506 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 8079 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 62000 | 0.390 |
4 | 33064 | 0.385 |
8 | 91570 | 0.380 |
1 | 100000 | 0.370 |
4 | 24220 | 0.360 |
Price($) | Vol. | No. |
---|---|---|
0.410 | 41895 | 3 |
0.415 | 130388 | 7 |
0.420 | 550003 | 10 |
0.425 | 39700 | 3 |
0.430 | 13701 | 3 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online